Hormonal
GLP-1 receptor agonists (e.g., exenatide, liraglutide, semaglutide) effectively treat type 2 diabetes and obesity by stimulating glucose-dependent insulin secretion, inhibiting glucagon secretion, slowing gastric emptying, and reducing appetite.
GLP-1 receptor agonists are a highly effective, FDA-approved class of medications for treating type 2 diabetes and obesity. They work by mimicking a natural gut hormone to increase insulin when blood sugar is high, decrease glucagon, slow digestion, and reduce appetite. While they can cause initial nausea, this is often manageable with slow dose increases. They offer the added benefit of cardiovascular protection for many patients.
GLP-1 directly augments glucose-dependent insulin biosynthesis and secretion from β cells... GLP-1 — in contrast to GIP — also powerfully inhibits glucagon secretion... infusions of GLP-1 in humans inhibited appetite and food intake, actions subsequently exploited in the clinic to treat obesity.
Why this rating
The paper reviews decades of research, multiple Phase 3 clinical trials, and the approval of multiple drugs (exenatide, liraglutide, semaglutide, teduglutide) for human use.
Source
Discovery, characterization, and clinical development of the glucagon-like peptides
Daniel J. Drucker et al. · Journal of Clinical Investigation · 2017
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →